Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 3.40 (0.20%)
Spread: 0.40 (0.023%)
Open: 1,701.60
High: 1,713.00
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

10 Jun 2014 17:55

YOUR MONEY-How to find value, as well as growth, in drug stocks

(The author is a Reuters contributor. The opinions expressed are his own.) By Conrad de Aenlle June 10, (Reuters) - Drugmakers have become fond of one another. The value of mergers in the industry was 20.9 percent higher in the first quarter than the fourth, reaching $44.9 billi

Read more
9 Jun 2014 17:09

DIRECTOR DEALINGS: Glaxo Senior Executive's Connected Person Acquires ADSs

LONDON (Alliance News) - GlaxoSmithKline PLC Monday said K Slaoui, connected person of divisional chairman Moncef Slaoui, bought 4 American Depositary Shares under the GSK 401K plan at a price of USD53.70 per ADS. Glaxo ADR shares were up 0.4% at USD53.92 Monday afternoon. By Rowena H

Read more
5 Jun 2014 14:20

Glaxo Starts Phase III Study For Iosmapimod For Acute Coronary Syndrome

LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday that it has begun a phase III study to evaluate its Iosmapimod drug in patients with acute coronary syndrome. The study will evaluate whether the drug can reduce the risk of cardiac events such as heart attacks when administered twi

Read more
5 Jun 2014 12:31

UK MIDDAY BRIEFING: ECB Cuts Rates, More To Follow

LONDON (Alliance News) - The European Central Bank on Thursday cut its key interest rate to a record low and embraced a negative deposit rate, the first for a leading central bank, as it tries to fight the low inflation that is threatening to derail the euro area's fragile economic recovery.Read more

5 Jun 2014 10:31

TOP NEWS: GlaxoSmithKline Agrees USD105 Million US Settlement

LONDON (Alliance News) - The following is a summary of top news stories Thursday.
----------
COMPANIES
----------
UK pharmaceutical giant GlaxoSmithKline PLC has agreed to a USD105 million settlement covering 44 US states over allegations t

Read more
5 Jun 2014 07:33

UK MORNING BRIEFING: ASOS Drags Down AIM Ahead Of ECB Meeting

LONDON (Alliance News) - ASOS is dragging down the AIM All-Share Index at the open Thursday after lowering its profit guidance. The online fashion retailer, by far the biggest AIM stock by market capitalisation, dropped 40% at the open and was down 34% a half hour into trading

Read more
5 Jun 2014 06:32

REPEAT: GlaxoSmithKline In USD105 Million Settlement With 44 US States

LONDON (Alliance News) - UK pharmaceutical giant GlaxoSmithKline PLC has agreed to a USD105 million settlement covering 44 US states over allegations that it unlawfully promoted its asthma treatment Advair and antidepressants Paxil and Wellburtin. As part of the settlement, announced on Wed

Read more
5 Jun 2014 06:23

GlaxoSmithKline Agrees USD105 Million Settlement With 44 US States

LONDON (Alliance News) - UK pharmaceutical giant GlaxoSmithKline PLC has agreed to a USD105 million settlement covering 44 US states over allegations that it unlawfully promoted its asthma treatment Advair and antidepressants Paxil and Wellburtin. As part of the settlement, announced on Wed

Read more
4 Jun 2014 18:46

UPDATE 1-GlaxoSmithKline in $105 mln settlement with US states over marketing

(Adds Glaxo comment, background) June 4 (Reuters) - British drugmaker GlaxoSmithKline Plc has agreed to pay $105 million to settle allegations by 44 U.S. states and the District of Columbia that it promoted its medicines for unapproved uses, several states attorneys general announced on W

Read more
4 Jun 2014 17:02

GlaxoSmithKline in $105 mln settlement with U.S. states over marketing

June 4 (Reuters) - British drugmaker GlaxoSmithKline Plc has agreed to pay $105 million to settle allegations by 44 U.S. states and the District of Columbia that it promoted its medicines for unapproved uses, several states attorneys general announced on Wednesday. Glaxo was accused of ill

Read more
2 Jun 2014 16:43

MARKET PULSE-Gigatronics, Everyware, Clovis Oncology, Arctic Cat

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks edged lower on Monday, falling from record levels as a weaker-than-expected read on m

Read more
2 Jun 2014 16:33

MARKET COMMENT: FTSE 100 Led Higher By Mining Constituents

LONDON (Alliance News) - The FTSE 100 started the month on the front foot Monday, closing higher, after a gauge of China's factory activity rose to a five-month high in May, suggesting the world's second-largest economy is stabilising after a subdued start to the year.

China's offic

Read more
2 Jun 2014 12:08

GSK signs deal with UK biotech firm to develop cancer drugs

GlaxoSmithKline (GSK) has signed a deal with a UK biotech company to develop new cancer drugs. GSK will pay Adaptimmune as much as $350m over the next seven years. Adaptimmune and GSK will work together to develop cell-based cancer therapies that involve re-engineering patients' white blood cells

Read more
2 Jun 2014 11:02

UK MIDDAY BRIEFING: Glaxo In Collaboration On Cancer Drugs

LONDON (Alliance News) - GlaxoSmithKline has signed a collaboration and licensing agreement with UK-based biotechnology company Adaptimmune Ltd for its cancer programme, a move that comes just weeks after it agreed to sell its own cancer drug business to Novartis as part of a

Read more
2 Jun 2014 10:02

REPEAT: Glaxo Signs Oncology Deal With Adaptimmune Worth USD350 Million

LONDON (Alliance News) - UK based biotechnology company Adaptimmune Ltd confirmed Monday that it had entered into a collaboration and licensing agreement with pharmaceutical giant GlaxoSmithKline PLC worth a potential USD350 million over the next seven years, for its cancer programme. Under

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.